Effects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity

Launched by PEKING UNIVERSITY THIRD HOSPITAL · Jan 9, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how a medication called benalutide, when combined with metformin and healthy lifestyle education, can help women with Polycystic Ovary Syndrome (PCOS) and obesity achieve pregnancy. The main goal is to see if this combination improves the chances of having a live birth compared to just using metformin with lifestyle education. The study will focus on women who are planning to conceive and have a specific body mass index (BMI) between 28 and 35.

To participate in this trial, women must have PCOS and want to become pregnant. However, certain health conditions like severe heart disease or liver problems, as well as specific medications taken recently, may exclude them from joining. The trial is not yet recruiting participants, but once it starts, those who are eligible can expect guidance on healthy lifestyle choices along with the treatments being studied. This research aims to provide better options for women facing difficulties with fertility due to PCOS and obesity.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Women with a wish to conceive; Women with PCOS (Rotterdam criteria); 28 kg/m2≤BMI\<35kg/m2;
• Exclusion Criteria:
• • Women with medical morbidity; Endocrine disorders; Abnormalities in liver and kidney function; Other medications such as glucocorticoids, anti-androgen drugs ;(spironolactone, cyproterone acetate, flutamide, etc.) within the last 3 months; Acute infections, severe cardiovascular disease, malignant tumors; Ongoing weight loss therapy (\>5% weight loss in the last 3 months) or history of gastrointestinal surgery; Uterine anomalies or untreated tubal hydrosalpinx; Receiving a donor oocyte or donor sperm cycle; Chromosome abnormality or recurrent miscarriage; planning preimplantation genetic testing (PGT); Any other contraindications to fertility treatment; Allergic to or contraindicated for GLP-1 class medications.